drugset / Trial / NCT02521077

Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer

NCT02521077

RandomizedParallel-groupTriple-blindSupportive care

Summary

This is a parallel-track, randomized study will observe whether intravenous ascorbic acid reduces the reported fatigue in women receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer.

Timeline

Start
2017-05
Primary completion
2019-03
Completion
2019-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Vitamin C Other / unclassified 50 g Intravenous

Indications

No indication recorded.